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Abstract
Cardiovascular disease (CVD) is one of the most 
prevalent illnesses worldwide and the leading cause of 
death in the U.S. Obstructive sleep apnea (OSA) has been 
found to be a risk factor correlated to CVD. Therefore, the 
following clinical question arises: [P] In an adult patient 
(35-75 years old) diagnosed with OSA, [I] does the use of 
CPAP [C: compared to patients with OSA who do not use 
CPAP] [O]decrease the risk and/or progression of CVD?
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Cardiovascular Disease
Ø Includes hypertension, stroke, heart failure, coronary 
artery disease (CAD) and atrial fibrillation
Ø Risk Factors: hyperlipidemia, family history of 
hypertension, obesity, smoking and diabetes
Obstructive Sleep Apnea
Ø Described as repetitive episodes of apnea, or 
cessation of breathing, during sleep
Ø Risk Factors: obesity, oropharyngeal abnormalities, 
increased neck circumference, male sex and smoking
Ø Treatment: Continuous Positive Airway Pressure 
(CPAP)
Intervention
Ø Decreases apnea and hypopnea during sleep, 
reducing negative effects on cardiovascular system
Introduction
Methods




Search terms: “continuous positive airway pressure AND 
cardiovascular AND obstructive sleep apnea”
Inclusion Criteria
Ø Randomized controlled trials within last 5 years
Ø Human subjects
Ø Written in English
Exclusion Criteria
Ø Subject size with n < 100
Ø Total trial length < 12 months
Ø Subject age range outside 35-75 years old
Ø Studies without a controlled trial
Ø Studies containing only one gender
3/6 are considered adequately valid while the 
remaining 3/6 are considered marginal
Strengths
Ø 5/6 include factor of CPAP compliance
Ø 4/6 statistically significant for increased survival of 
patients 
Ø Consistency of criteria used in majority of articles 
offers stronger correlation
Ø Sample sizes
Ø No studies are considered inadequate
Limitations
Ø Role of comorbidities in disease
Ø Bias varies throughout studies
Ø Variation of trial duration
Ø Recruitment methods
Future Research
Ø Improve screening methods for OSA
Ø Continue long-term research on effects of 
treatment of OSA on progression of CVD
Ø Cost effectiveness
Discussion 
Table 1. Comparison of Study Designs
Results 
The Use of Continuous Positive Airway Pressure in Patients with Obstructive Sleep 
Apnea to Decrease the Risk and Progression of Cardiovascular Disease
Statistically significant increase in overall survival 
through use of long-term CPAP 
Not enough evidence to support a change in current 
clinical practice. However, it can be suggested for 
better screening practices for OSA can be 
implemented. 
Encouragement of CPAP treatment due to mask 
discomfort and financial responsibility are still major 
factor that will impact future use in clinical practice.
Conclusion
RCT = randomized control trial; AHI = apnea/hypopnea events/h; N/A = not applicable 
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434 43-68 AHI levels 81.3 4 hrs per night/5 days per week
Vascular events; 
survival
3 Double Blind RCT 2,687 45-75 SatO2 drops ³ 4% 44
3 hrs during 1-week run-






235 54-75 AHI³20 24; 68 4 hrs per night/70% of days
Vascular events; 
survival
5 Single Blind RCT 70 41-65 AHI>15 12 4 hrs per night/70% of days AHI; vascular events
6 Quantitative 220 56-74 N/A 12 N/A Survival
